We have high qualified groups and advanced technologies to perform TCR engineering services covering every unit of manufacturing and delivery pipeline. From a tumor-reactive T cell or active anti-tumor T-cell antigens, the appropriate target sequence is introduced to modify T cells to target a broad range of tumors with improved specificity. With engineering TCR construction and a series of assay, such as transgene expression, TCR/CD3 stability, lymphocyte antigen reactivity and cytotoxicity, animal experiments, etc., we provide cGMP-compliant TCR products for preclinical and clinical trials. Learn more about TCR T cells. https://www.creative-biolabs.com/car-t/cellrapeutics-tcr-technology.htm
